ID   KPCL_HUMAN              Reviewed;         683 AA.
AC   P24723; B4DJN5; Q16246; Q8NE03;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-2009, sequence version 4.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=Protein kinase C eta type;
DE            EC=2.7.11.13;
DE   AltName: Full=PKC-L;
DE   AltName: Full=nPKC-eta;
GN   Name=PRKCH; Synonyms=PKCL, PRKCL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Lung;
RX   PubMed=1986216; DOI=10.1128/MCB.11.1.126;
RA   Bacher N., Zisman Y., Berent E., Livneh E.;
RT   "Isolation and characterization of PKC-L, a new member of the protein
RT   kinase C-related gene family specifically expressed in lung, skin, and
RT   heart.";
RL   Mol. Cell. Biol. 11:126-133(1991).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION.
RX   PubMed=1545821;
RA   Bacher N., Zisman Y., Berent E., Livneh E.;
RL   Mol. Cell. Biol. 12:1404-1404(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 438-539 (ISOFORM 1).
RX   PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Identification of multiple, novel, protein kinase C-related gene
RT   products.";
RL   FEBS Lett. 356:5-8(1994).
RN   [8]
RP   FUNCTION.
RX   PubMed=11112424; DOI=10.1006/bbrc.2000.3903;
RA   Akkaraju G.R., Basu A.;
RT   "Overexpression of protein kinase C-eta attenuates caspase activation
RT   and tumor necrosis factor-alpha-induced cell death.";
RL   Biochem. Biophys. Res. Commun. 279:103-107(2000).
RN   [9]
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=10806212; DOI=10.1074/jbc.M003203200;
RA   Hussaini I.M., Karns L.R., Vinton G., Carpenter J.E., Redpath G.T.,
RA   Sando J.J., VandenBerg S.R.;
RT   "Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific
RT   proliferative response in astrocytic tumor cells.";
RL   J. Biol. Chem. 275:22348-22354(2000).
RN   [10]
RP   FUNCTION.
RX   PubMed=11772428; DOI=10.1093/neuonc/4.1.9;
RA   Hussaini I.M., Carpenter J.E., Redpath G.T., Sando J.J.,
RA   Shaffrey M.E., Vandenberg S.R.;
RT   "Protein kinase C-eta regulates resistance to UV- and gamma-
RT   irradiation-induced apoptosis in glioblastoma cells by preventing
RT   caspase-9 activation.";
RL   Neuro-oncol. 4:9-21(2002).
RN   [11]
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=15489897; DOI=10.1038/sj.onc.1208093;
RA   Aeder S.E., Martin P.M., Soh J.W., Hussaini I.M.;
RT   "PKC-eta mediates glioblastoma cell proliferation through the Akt and
RT   mTOR signaling pathways.";
RL   Oncogene 23:9062-9069(2004).
RN   [12]
RP   INTERACTION WITH DGKQ.
RX   PubMed=15632189; DOI=10.1074/jbc.M409301200;
RA   van Baal J., de Widt J., Divecha N., van Blitterswijk W.J.;
RT   "Translocation of diacylglycerol kinase theta from cytosol to plasma
RT   membrane in response to activation of G protein-coupled receptors and
RT   protein kinase C.";
RL   J. Biol. Chem. 280:9870-9878(2005).
RN   [13]
RP   FUNCTION.
RX   PubMed=17146445; DOI=10.1038/sj.onc.1210090;
RA   Uht R.M., Amos S., Martin P.M., Riggan A.E., Hussaini I.M.;
RT   "The protein kinase C-eta isoform induces proliferation in
RT   glioblastoma cell lines through an ERK/Elk-1 pathway.";
RL   Oncogene 26:2885-2893(2007).
RN   [14]
RP   FUNCTION IN B-CELL SIGNALING.
RX   PubMed=18780722; DOI=10.1093/intimm/dxn101;
RA   Oda A., Ono T., Yamamoto M., Goitsuka R., Kitamura D.;
RT   "PKC eta directs induction of IRF-4 expression and Ig kappa gene
RT   rearrangement in pre-BCR signaling pathway.";
RL   Int. Immunol. 20:1417-1426(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF OCLN.
RX   PubMed=19114660; DOI=10.1073/pnas.0802741106;
RA   Suzuki T., Elias B.C., Seth A., Shen L., Turner J.R., Giorgianni F.,
RA   Desiderio D., Guntaka R., Rao R.;
RT   "PKC eta regulates occludin phosphorylation and epithelial tight
RT   junction integrity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:61-66(2009).
RN   [17]
RP   FUNCTION.
RX   PubMed=20558593; DOI=10.1124/mol.110.064394;
RA   Lee H.K., Yeo S., Kim J.S., Lee J.G., Bae Y.S., Lee C., Baek S.H.;
RT   "Protein kinase C-eta and phospholipase D2 pathway regulates foam cell
RT   formation via regulator of G protein signaling 2.";
RL   Mol. Pharmacol. 78:478-485(2010).
RN   [18]
RP   FUNCTION.
RX   PubMed=21820409; DOI=10.1016/j.bbrc.2011.07.090;
RA   Raveh-Amit H., Hai N., Rotem-Dai N., Shahaf G., Gopas J., Livneh E.;
RT   "Protein kinase C? activates NF-?B in response to camptothecin-induced
RT   DNA damage.";
RL   Biochem. Biophys. Res. Commun. 412:313-317(2011).
RN   [19]
RP   REVIEW.
RX   PubMed=12473186; DOI=10.1093/oxfordjournals.jbchem.a003297;
RA   Kashiwagi M., Ohba M., Chida K., Kuroki T.;
RT   "Protein kinase C eta (PKC eta): its involvement in keratinocyte
RT   differentiation.";
RL   J. Biochem. 132:853-857(2002).
RN   [20]
RP   FUNCTION.
RX   PubMed=22304920; DOI=10.1016/j.cell.2012.01.016;
RA   Lau E., Kluger H., Varsano T., Lee K., Scheffler I., Rimm D.L.,
RA   Ideker T., Ronai Z.A.;
RT   "PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while
RT   blocking its apoptotic function at mitochondria.";
RL   Cell 148:543-555(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-656, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-138, PHOSPHORYLATION AT
RP   SER-28 AND SER-32, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16973127; DOI=10.1016/j.bbrc.2006.08.160;
RA   Littler D.R., Walker J.R., She Y.-M., Finerty P.J. Jr., Newman E.M.,
RA   Dhe-Paganon S.;
RT   "Structure of human protein kinase C eta (PKCeta) C2 domain and
RT   identification of phosphorylation sites.";
RL   Biochem. Biophys. Res. Commun. 349:1182-1189(2006).
RN   [24]
RP   ASSOCIATION OF VARIANT ILE-374 WITH ISCHSTR, AND CHARACTERIZATION OF
RP   VARIANT ILE-374.
RX   PubMed=17206144; DOI=10.1038/ng1945;
RA   Kubo M., Hata J., Ninomiya T., Matsuda K., Yonemoto K., Nakano T.,
RA   Matsushita T., Yamazaki K., Ohnishi Y., Saito S., Kitazono T.,
RA   Ibayashi S., Sueishi K., Iida M., Nakamura Y., Kiyohara Y.;
RT   "A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the
RT   risk of cerebral infarction.";
RL   Nat. Genet. 39:212-217(2007).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-19; ARG-65; GLN-149; GLN-359;
RP   ILE-374; ALA-575; ILE-594 AND SER-612.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol
CC       (DAG)-dependent serine/threonine-protein kinase that is involved
CC       in the regulation of cell differentiation in keratinocytes and
CC       pre-B cell receptor, mediates regulation of epithelial tight
CC       junction integrity and foam cell formation, and is required for
CC       glioblastoma proliferation and apoptosis prevention in MCF-7
CC       cells. In keratinocytes, binds and activates the tyrosine kinase
CC       FYN, which in turn blocks epidermal growth factor receptor (EGFR)
CC       signaling and leads to keratinocyte growth arrest and
CC       differentiation. Associates with the cyclin CCNE1-CDK2-CDKN1B
CC       complex and inhibits CDK2 kinase activity, leading to RB1
CC       dephosphorylation and thereby G1 arrest in keratinocytes. In
CC       association with RALA activates actin depolymerization, which is
CC       necessary for keratinocyte differentiation. In the pre-B cell
CC       receptor signaling, functions downstream of BLNK by up-regulating
CC       IRF4, which in turn activates L chain gene rearrangement.
CC       Regulates epithelial tight junctions (TJs) by phosphorylating
CC       occludin (OCLN) on threonine residues, which is necessary for the
CC       assembly and maintenance of TJs. In association with PLD2 and via
CC       TLR4 signaling, is involved in lipopolysaccharide (LPS)-induced
CC       RGS2 down-regulation and foam cell formation. Upon PMA
CC       stimulation, mediates glioblastoma cell proliferation by
CC       activating the mTOR pathway, the PI3K/AKT pathway and the ERK1-
CC       dependent phosphorylation of ELK1. Involved in the protection of
CC       glioblastoma cells from irradiation-induced apoptosis by
CC       preventing caspase-9 activation. In camptothecin-treated MCF-7
CC       cells, regulates NF-kappa-B upstream signaling by activating
CC       IKBKB, and confers protection against DNA damage-induced
CC       apoptosis. Promotes oncogenic functions of ATF2 in the nucleus
CC       while blocking its apoptotic function at mitochondria.
CC       Phosphorylates ATF2 which promotes its nuclear retention and
CC       transcriptional activity and negatively regulates its
CC       mitochondrial localization. {ECO:0000269|PubMed:10806212,
CC       ECO:0000269|PubMed:11112424, ECO:0000269|PubMed:11772428,
CC       ECO:0000269|PubMed:15489897, ECO:0000269|PubMed:17146445,
CC       ECO:0000269|PubMed:18780722, ECO:0000269|PubMed:19114660,
CC       ECO:0000269|PubMed:20558593, ECO:0000269|PubMed:21820409,
CC       ECO:0000269|PubMed:22304920}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are
CC       calcium-insensitive, but activated by diacylglycerol (DAG) and
CC       phosphatidylserine. Three specific sites; Thr-513 (activation loop
CC       of the kinase domain), Thr-656 (turn motif) and Ser-675
CC       (hydrophobic region), need to be phosphorylated for its full
CC       activation.
CC   -!- SUBUNIT: Interacts with FYN and RALA (By similarity). Interacts
CC       with DGKQ. {ECO:0000250, ECO:0000269|PubMed:15632189}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P24723-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P24723-2; Sequence=VSP_056572;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Most abundant in lung, less in heart and skin.
CC       {ECO:0000269|PubMed:1986216}.
CC   -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type
CC       region 1 (C1A) and 2 (C1B), is the diacylglycerol sensor and the
CC       C2 domain is a non-calcium binding domain.
CC   -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an
CC       acute neurologic event leading to death of neural tissue of the
CC       brain and resulting in loss of motor, sensory and/or cognitive
CC       function. Ischemic strokes, resulting from vascular occlusion, is
CC       considered to be a highly complex disease consisting of a group of
CC       heterogeneous disorders with multiple genetic and environmental
CC       risk factors. {ECO:0000269|PubMed:17206144}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M55284; AAA60100.1; -; mRNA.
DR   EMBL; AK290183; BAF82872.1; -; mRNA.
DR   EMBL; AK296158; BAG58897.1; -; mRNA.
DR   EMBL; AL138996; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355916; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL359220; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471061; EAW80800.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW80801.1; -; Genomic_DNA.
DR   EMBL; BC037268; AAH37268.1; -; mRNA.
DR   EMBL; S74620; AAB32724.1; -; mRNA.
DR   CCDS; CCDS9752.1; -. [P24723-1]
DR   PIR; A39666; A39666.
DR   RefSeq; NP_006246.2; NM_006255.4. [P24723-1]
DR   RefSeq; XP_016876947.1; XM_017021458.1. [P24723-2]
DR   UniGene; Hs.333907; -.
DR   PDB; 2FK9; X-ray; 1.75 A; A=1-138.
DR   PDB; 3TXO; X-ray; 2.05 A; A=333-683.
DR   PDBsum; 2FK9; -.
DR   PDBsum; 3TXO; -.
DR   ProteinModelPortal; P24723; -.
DR   SMR; P24723; -.
DR   BioGrid; 111569; 12.
DR   DIP; DIP-44588N; -.
DR   IntAct; P24723; 5.
DR   MINT; MINT-3973608; -.
DR   STRING; 9606.ENSP00000329127; -.
DR   BindingDB; P24723; -.
DR   ChEMBL; CHEMBL3616; -.
DR   GuidetoPHARMACOLOGY; 1487; -.
DR   iPTMnet; P24723; -.
DR   PhosphoSitePlus; P24723; -.
DR   BioMuta; PRKCH; -.
DR   DMDM; 281185512; -.
DR   EPD; P24723; -.
DR   MaxQB; P24723; -.
DR   PaxDb; P24723; -.
DR   PeptideAtlas; P24723; -.
DR   PRIDE; P24723; -.
DR   DNASU; 5583; -.
DR   Ensembl; ENST00000332981; ENSP00000329127; ENSG00000027075. [P24723-1]
DR   Ensembl; ENST00000555082; ENSP00000450981; ENSG00000027075. [P24723-2]
DR   GeneID; 5583; -.
DR   KEGG; hsa:5583; -.
DR   UCSC; uc001xfn.4; human. [P24723-1]
DR   CTD; 5583; -.
DR   DisGeNET; 5583; -.
DR   GeneCards; PRKCH; -.
DR   HGNC; HGNC:9403; PRKCH.
DR   HPA; HPA026294; -.
DR   HPA; HPA053709; -.
DR   MalaCards; PRKCH; -.
DR   MIM; 601367; phenotype.
DR   MIM; 605437; gene.
DR   neXtProt; NX_P24723; -.
DR   OpenTargets; ENSG00000027075; -.
DR   PharmGKB; PA33767; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOGENOM; HOG000233022; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P24723; -.
DR   KO; K18051; -.
DR   OMA; YLKVRIG; -.
DR   OrthoDB; EOG091G0QRS; -.
DR   PhylomeDB; P24723; -.
DR   TreeFam; TF351133; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-114508; Effects of PIP2 hydrolysis.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   SABIO-RK; P24723; -.
DR   SignaLink; P24723; -.
DR   SIGNOR; P24723; -.
DR   ChiTaRS; PRKCH; human.
DR   EvolutionaryTrace; P24723; -.
DR   GeneWiki; PRKCH; -.
DR   GenomeRNAi; 5583; -.
DR   PRO; PR:P24723; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000027075; -.
DR   CleanEx; HS_PRKCH; -.
DR   ExpressionAtlas; P24723; baseline and differential.
DR   Genevisible; P24723; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004699; F:calcium-independent protein kinase C activity; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004697; F:protein kinase C activity; TAS:ProtInc.
DR   GO; GO:0017160; F:Ral GTPase binding; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0070528; P:protein kinase C signaling; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:2000810; P:regulation of bicellular tight junction assembly; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05590; STKc_nPKC_eta; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR034665; nPKC_eta.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR027431; PKC_eta.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR014376; Prot_kin_PKC_delta.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000551; PKC_delta; 1.
DR   PIRSF; PIRSF501107; Protein_kin_C_eta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Differentiation; Kinase; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    683       Protein kinase C eta type.
FT                                /FTId=PRO_0000055705.
FT   DOMAIN       12    113       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      355    614       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      615    683       AGC-kinase C-terminal.
FT   ZN_FING     171    222       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     245    295       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     361    369       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    479    479       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     384    384       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      28     28       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000305|PubMed:16973127}.
FT   MOD_RES      32     32       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:16973127}.
FT   MOD_RES     317    317       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23298}.
FT   MOD_RES     513    513       Phosphothreonine; by PDPK1.
FT                                {ECO:0000305}.
FT   MOD_RES     656    656       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     675    675       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q64617}.
FT   VAR_SEQ       1    161       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056572.
FT   VARIANT      19     19       A -> V (in dbSNP:rs55645551).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042312.
FT   VARIANT      65     65       K -> R (in dbSNP:rs55737090).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042313.
FT   VARIANT     149    149       R -> Q (in dbSNP:rs55848048).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042314.
FT   VARIANT     359    359       R -> Q (in dbSNP:rs55818778).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042315.
FT   VARIANT     374    374       V -> I (associated with susceptibility to
FT                                ischemic stroke; increases
FT                                autophosphorylation and kinase activity;
FT                                dbSNP:rs2230500).
FT                                {ECO:0000269|PubMed:17206144,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034604.
FT   VARIANT     497    497       D -> Y (in dbSNP:rs11846991).
FT                                /FTId=VAR_060736.
FT   VARIANT     575    575       T -> A (in a aLL TEL/AML1+ sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042316.
FT   VARIANT     594    594       T -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042317.
FT   VARIANT     612    612       P -> S (in dbSNP:rs34159231).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042318.
FT   VARIANT     645    645       D -> V (in dbSNP:rs35561533).
FT                                /FTId=VAR_042438.
FT   CONFLICT     96     96       Missing (in Ref. 1; AAA60100).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       L -> R (in Ref. 1; AAA60100).
FT                                {ECO:0000305}.
FT   CONFLICT    110    110       R -> G (in Ref. 1; AAA60100).
FT                                {ECO:0000305}.
FT   CONFLICT    393    393       Q -> L (in Ref. 1; AAA60100).
FT                                {ECO:0000305}.
FT   CONFLICT    472    472       D -> E (in Ref. 7; AAB32724).
FT                                {ECO:0000305}.
FT   STRAND        8     20       {ECO:0000244|PDB:2FK9}.
FT   HELIX        26     30       {ECO:0000244|PDB:2FK9}.
FT   TURN         31     33       {ECO:0000244|PDB:2FK9}.
FT   STRAND       34     37       {ECO:0000244|PDB:2FK9}.
FT   STRAND       43     49       {ECO:0000244|PDB:2FK9}.
FT   STRAND       52     56       {ECO:0000244|PDB:2FK9}.
FT   STRAND       67     79       {ECO:0000244|PDB:2FK9}.
FT   STRAND       81     88       {ECO:0000244|PDB:2FK9}.
FT   STRAND       91     94       {ECO:0000244|PDB:2FK9}.
FT   STRAND       96    104       {ECO:0000244|PDB:2FK9}.
FT   HELIX       105    112       {ECO:0000244|PDB:2FK9}.
FT   STRAND      116    123       {ECO:0000244|PDB:2FK9}.
FT   STRAND      125    127       {ECO:0000244|PDB:2FK9}.
FT   STRAND      129    137       {ECO:0000244|PDB:2FK9}.
FT   STRAND      355    364       {ECO:0000244|PDB:3TXO}.
FT   STRAND      367    374       {ECO:0000244|PDB:3TXO}.
FT   TURN        375    377       {ECO:0000244|PDB:3TXO}.
FT   STRAND      380    387       {ECO:0000244|PDB:3TXO}.
FT   HELIX       388    394       {ECO:0000244|PDB:3TXO}.
FT   HELIX       397    409       {ECO:0000244|PDB:3TXO}.
FT   TURN        410    412       {ECO:0000244|PDB:3TXO}.
FT   STRAND      419    424       {ECO:0000244|PDB:3TXO}.
FT   STRAND      426    434       {ECO:0000244|PDB:3TXO}.
FT   HELIX       441    448       {ECO:0000244|PDB:3TXO}.
FT   HELIX       453    472       {ECO:0000244|PDB:3TXO}.
FT   HELIX       482    484       {ECO:0000244|PDB:3TXO}.
FT   STRAND      485    487       {ECO:0000244|PDB:3TXO}.
FT   STRAND      493    495       {ECO:0000244|PDB:3TXO}.
FT   HELIX       518    520       {ECO:0000244|PDB:3TXO}.
FT   HELIX       523    530       {ECO:0000244|PDB:3TXO}.
FT   HELIX       534    549       {ECO:0000244|PDB:3TXO}.
FT   HELIX       559    568       {ECO:0000244|PDB:3TXO}.
FT   HELIX       579    588       {ECO:0000244|PDB:3TXO}.
FT   HELIX       593    595       {ECO:0000244|PDB:3TXO}.
FT   HELIX       600    602       {ECO:0000244|PDB:3TXO}.
FT   HELIX       606    609       {ECO:0000244|PDB:3TXO}.
FT   HELIX       612    614       {ECO:0000244|PDB:3TXO}.
FT   HELIX       619    623       {ECO:0000244|PDB:3TXO}.
FT   HELIX       646    649       {ECO:0000244|PDB:3TXO}.
FT   HELIX       663    665       {ECO:0000244|PDB:3TXO}.
FT   HELIX       668    671       {ECO:0000244|PDB:3TXO}.
SQ   SEQUENCE   683 AA;  77828 MW;  0A29806CE31912F2 CRC64;
     MSSGTMKFNG YLRVRIGEAV GLQPTRWSLR HSLFKKGHQL LDPYLTVSVD QVRVGQTSTK
     QKTNKPTYNE EFCANVTDGG HLELAVFHET PLGYDHFVAN CTLQFQELLR TTGASDTFEG
     WVDLEPEGKV FVVITLTGSF TEATLQRDRI FKHFTRKRQR AMRRRVHQIN GHKFMATYLR
     QPTYCSHCRE FIWGVFGKQG YQCQVCTCVV HKRCHHLIVT ACTCQNNINK VDSKIAEQRF
     GINIPHKFSI HNYKVPTFCD HCGSLLWGIM RQGLQCKICK MNVHIRCQAN VAPNCGVNAV
     ELAKTLAGMG LQPGNISPTS KLVSRSTLRR QGKESSKEGN GIGVNSSNRL GIDNFEFIRV
     LGKGSFGKVM LARVKETGDL YAVKVLKKDV ILQDDDVECT MTEKRILSLA RNHPFLTQLF
     CCFQTPDRLF FVMEFVNGGD LMFHIQKSRR FDEARARFYA AEIISALMFL HDKGIIYRDL
     KLDNVLLDHE GHCKLADFGM CKEGICNGVT TATFCGTPDY IAPEILQEML YGPAVDWWAM
     GVLLYEMLCG HAPFEAENED DLFEAILNDE VVYPTWLHED ATGILKSFMT KNPTMRLGSL
     TQGGEHAILR HPFFKEIDWA QLNHRQIEPP FRPRIKSRED VSNFDPDFIK EEPVLTPIDE
     GHLPMINQDE FRNFSYVSPE LQP
//
